REFERENCES
- Brylewski, J. and Duggan, L. (1999). Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomised controlled trials. Journal of Intellectual Disability Research, 43, 360–371.
- Bokszanska, A., Martin, G., Vanstraelen, M., Holt, G., Bouras, N. and Taylor, D. (2003). Risperidone and Olanzapine in adults with intellectual disability: a clinical naturalistic study. International Clinical Psychophamacology, 18, 285–291.
- Dalvi, M., Thalayasingam, S. P and George, G. R. (2003). Audit on high dose antipsychotic medication in three tertiary services for people with Learning Disability. The British Journal of Developmental Disability, 49, 117–124.
- Deb. S., Clarke, D. and Unwin, G. (2006). Using Medication to manage behaviour problems among adults with a Learning Disability. Quick Reference Guide. Royal College of Psychiatrists.
- Department of Health (2001). Valuing People: A New Strategy for Learning Disability for the 21st Century.
- Fernando, L., Regan, A. and Khwaja, M. (1997). Audit of antipsychotic medication usage in the community in a sample of people with Learning Disabilities. The British Journal of Developmental Disability, 43, 163–169.
- Friedlander, R., Lazar, S. and Klancnik, J. (2001). Atypical Antipsychotic Use in Treating Adolescents and Young Adults with Developmental Disability. The Canadian Journal of Psychiatry, 46,741–745
- King, B.H. (2002). Psychopharmacology in mental retardation. Current Opinion Psychiatry, 15,497–502.
- Royal College of Psychiatrists (1994). Consensus statement on the use of high dose antipsychotic medication.
- Sachdev, P S. (1991). Psychoactive drug use in an institution for intellectually handicapped persons. The Medical Journal of Australia, 155, 75–79.
- Thompson, C. (1994). Consensus Statement on The Use of High-Dose Antipsychotic Medication. British Journal of Psychiatry, 164, 448–458.